The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | Supportive care and prophylaxis of the side effects of myeloma drugs
Heinz Ludwig, MD, PhD, of Wilhelminen Cancer Research Institute, Vienna, Austria, talks about the importance and advantages of supportive care for patients with multiple myeloma (MM). Dr Wilhelminen discusses the new advances for prophylaxis, particularly thromboprophylaxis. Secondly, he discusses the risks of cardiotoxicity caused by many MM drugs and how to supportively care for patients. Finally, Dr Wilhelminen discusses thrombotic microangiopathy, which he says is considered an emergency state. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
